Literature DB >> 3801272

Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.

A Thyss, M Schneider, J Santini, C Caldani, J Vallicioni, P Chauvel, F Demard.   

Abstract

One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment. The regimen consisted of cis-platinum 100 mg m-2 on day 1 and 5-fluorouracil 1000 mg m-2 on days 2-6; drugs were administered by continuous infusion. The toxicity of this protocol was acceptable, as 82% of the patients were able to receive the initially scheduled drug dose. The overall response rate of 86.5% included a 35% rate of complete lesion regression. The effect of this regimen on primary tumours was especially remarkable--87.5% responses, including 47.5% complete responses. Results for lymph node metastases were not as good--66% responses, including 33% complete responses. The best results were obtained for tumours of the oropharynx and hypopharynx; oral cavity lesions were the most refractory. For those patients who were subsequently operated on, histological examination of the surgical specimen either confirmed sterilization or demonstrated the persistence of small disease foci. After local treatment, which consisted of radiotherapy alone for 69% of patients, the lesion control rate was 80%. At 18 months follow-up, the survival rate for patients who achieved a complete response with chemotherapy was significantly better than that for patients with a response of less than 50%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801272      PMCID: PMC2001551          DOI: 10.1038/bjc.1986.237

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  A multidisciplinary therapeutic approach for advanced previously untreated epidermoid cancer of the head and neck: preliminary report.

Authors:  M Al-Sarraf; M H Amer; G Vaishampayan; J Loh; A Weaver
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

2.  Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

Authors:  M Rooney; J Kish; J Jacobs; J Kinzie; A Weaver; J Crissman; M Al-Sarraf
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

3.  Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx.

Authors:  J T Fazekas; C Sommer; S Kramer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-05       Impact factor: 7.038

4.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

5.  The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study.

Authors:  J H Glick; V Marcial; M Richter; E Velez-Garcia
Journal:  Cancer       Date:  1980-11-01       Impact factor: 6.860

6.  Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate-leucovorin prior to definitive radiotherapy or surgery.

Authors:  T J Ervin; J Kirkwood; R R Weichselbaum; D Miller; S W Pitman; E Frei
Journal:  Laryngoscope       Date:  1981-07       Impact factor: 3.325

7.  The incidence of metastases after multimodal therapy for cancer of the head and neck.

Authors:  G J Slotman; T Mohit; S Raina; A P Swaminathan; M Ohanian; B F Rush
Journal:  Cancer       Date:  1984-11-01       Impact factor: 6.860

8.  Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.

Authors:  J Kish; A Drelichman; J Jacobs; J Hoschner; J Kinzie; J Loh; A Weaver; M Al-Sarraf
Journal:  Cancer Treat Rep       Date:  1982-03

9.  [Primary chemotherapy combining vincristine, bleomycin, methotrexate and cisplatin systemically or intra-arterially in cancers of the upper respiratory and digestive tracts].

Authors:  F Demard; M Schneider; J Vallicioni; P Chauvel; G Lesbats
Journal:  Ann Otolaryngol Chir Cervicofac       Date:  1983

10.  Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate.

Authors:  T J Ervin; R R Weichselbaum; R L Fabian; D Miller; C M Norris; M R Posner; C Rose; P Lockhart; S A Tuttle; J M MacIntyre
Journal:  Arch Otolaryngol       Date:  1984-04
View more
  7 in total

Review 1.  Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer.

Authors:  Jeffrey M Vainshtein; Vivian F Wu; Matthew E Spector; Carol R Bradford; Gregory T Wolf; Francis P Worden
Journal:  Expert Rev Anticancer Ther       Date:  2013-09       Impact factor: 4.512

Review 2.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

3.  A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.

Authors:  M Trudeau; A Zukiwski; A Langleben; G Boos; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.

Authors:  M C Etienne; S Bernard; J L Fischel; P Formento; J Gioanni; J Santini; F Demard; M Schneider; G Milano
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

5.  No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.

Authors:  R A Fleming; G A Milano; M C Etienne; N Renée; A Thyss; M Schneider; F Demard
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

6.  An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.

Authors:  Vijay M Patil; Santam Chakraborty; T K Jithin; T P Sajith Babu; Satheesh Babu; Shiva Kumar; M S Biji; Atanu Bhattacharjee; Satheesan Balasubramanian
Journal:  South Asian J Cancer       Date:  2016 Apr-Jun

7.  Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.

Authors:  Yoshihiro Seto; Fumiyasu Okazaki; Keiji Horikawa; Jing Zhang; Hitoshi Sasaki; Hideto To
Journal:  BMC Cancer       Date:  2016-09-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.